Ischemix, Inc., a clinical-stage pharmaceutical company focused on hospital-acquired kidney and cardiac injury, announced today that Peter G. Milner, MD has been elected to its Board of Directors. David A. DeWahl, Jr., President and CEO of Ischemix said "Dr. Milner's breadth of experience in pharmaceutical development and regulatory approvals will enhance the progress of our leading drug candidate and pipeline toward regulatory and clinical acceptance. His participation on our Board is a real vote of confidence in our drug candidates and approach."
Dr. Milner is Chairman and co-founder of Armetheon, a private company conducting a Phase 3 trial of a novel oral anticoagulant. Previously he was CEO of Heart Metabolics, a private company addressing hypertrophic cardio-myopathy. Dr. Milner also co-founded Optivia Biotechnology, a leading transporter biology company as well as ARYx Therapeutics, where he served as CEO and President. Previously he co-founded cardiovascular company CV Therapeutics. Dr. Milner is a board certified cardiologist, a Fellow of the American College of Cardiology, and co-inventor on 50 patents and author of many original papers. He serves as adjunct clinical faculty at Stanford University and as a board member of the California Life Sciences Association.
"Dr. Milner, who will also join Ischemix' eminent Clinical Advisory Board, will bring impressive skills to guide this first direct cytoprotective drug into the marketplace" said Dr. Reinier Beeuwkes, Chairman of the Company. "Response to an unmet medical need and strong patent protection are not enough. Superb talent and experience make the critical difference."